Mercy Advances Cancer Care in Missouri with Multi-System, Multi-Hospital Agreement for Accuray Radiation Therapy Systems

SUNNYVALE, Calif., May 9, 2018 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today that the company has signed a multi-system, multi-hospital agreement with Mercy for the acquisition of Accuray Radixact^® and CyberKnife^® M6™ Systems, building on a 13-year relationship designed to expand access to advanced, life-saving technology for more cancer patients. The next-generation systems will replace existing Accuray devices as well as competitive conventional linear accelerators. The order was entered into backlog during the company's fourth fiscal quarter which ends June 30, 2018.

Mercy cares for millions of patients annually across four states and was recently named one of the top five large U.S. health systems by IBM Watson Health for the third consecutive year. It is the first health system in Missouri to acquire the Radixact and CyberKnife M6 Systems. The innovative agreement between Mercy and Accuray for these systems was reached through negotiations with ROi, which partners with technology leaders to drive better patient outcomes for its members and their patients.

"Mercy partnered with Accuray because we believe the company's radiation therapy systems offer an advanced and differentiated approach to treating cancer that provides clinical and financial value to our patients, clinical teams and hospitals, and reinforces our reputation as go-to providers for exceptional cancer care," said Steve Mackin, president of Mercy Hospital St. Louis and co-executive sponsor of Mercy's cancer care steering committee. "The Radixact Systems will ensure our patients have access to the most advanced radiotherapy options and provide our large oncology program with meaningful clinical and operational enhancements compared to our current TomoTherapy Systems, allowing our team to confidently deliver very accurate treatments in standard radiation therapy treatment times, while expanding the types of cases we are able to treat. The upgrade of our CyberKnife System will also increase our teams' efficiency and effectiveness, facilitating the delivery of highly precise radiosurgery and stereotactic body radiation therapy treatments to more patients each day."

"When the Radixact and CyberKnife Systems are installed in the St. Louis and Springfield, Missouri, area facilities, Mercy clinicians will have access to two of the industry's most advanced radiation therapy treatment delivery and planning systems, and the opportunity to experience the difference these devices can make to their practice and their patients during the routine cases they see every day, and the most complex cases when necessary," said Joshua H. Levine, President and Chief Executive Officer of Accuray. "Our long-term relationship with Mercy reflects a valued partnership based on a shared vision of putting the patient first. This multi-system, multi-hospital agreement with Mercy reinforces our commitment to delivering excellence in all aspects of our business – products, customer educational support and service."

Important Safety Information
For Important Safety Information please refer to https://www.accuray.com/safety-statement.

About Resource Optimization & Innovation (ROi)
Based in St. Louis, Missouri, ROi believes in the power of provider collaboration to transform health care. A recognized leader in supply chain management, ROi serves health care organizations across the United States that share a passion for supply chain excellence. As a provider-owned supply chain organization, ROi delivers a range of cost management and supply chain services, focusing on all aspects of supply chain from planning through fulfillment and consumption to ensure the highest quality of care is delivered in the most cost effective manner. For more information, visit: www.roiscs.com.

About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com or follow us on Facebook, LinkedIn, Twitter and YouTube.

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, and patient experiences and outcomes. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products, the company's ability to effectively manage its growth, the company's ability to maintain or increase its gross margins on product sales and services and such other risks identified under the heading "Risk Factors" in the company's annual report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2017, the company's quarterly report on Form 10-Q, filed with the SEC on May 2, 2018 and as updated periodically with the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

SOURCE Accuray Incorporated

Related Links

http://www.accuray.com